Source:http://linkedlifedata.com/resource/pubmed/id/17220566
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2007-1-15
|
pubmed:abstractText |
Amiodarone has pharmacokinetic interactions with a number of therapeutic drugs, including warfarin, phenytoin, flecainide, and cyclosporine. Metoprolol is mainly metabolized by CYP2D6, and desethylamiodarone, a metabolite of amiodarone, has a markedly greater inhibitory effect on CYP2D6 than amiodarone. Therefore, the goal of this study was to evaluate the effect of amiodarone and desethylamiodarone on the serum concentration/dose ratio (C/D) of metoprolol in 120 inpatients with cardiac arrhythmias that received either metoprolol and amiodarone (MET+AMD group, n=30) or metoprolol alone (MET group, n=90). The ratio of administered metoprolol was compared between the MET and the MET+AMD groups. The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01). Furthermore, a significant correlation was found between the C/D ratio and desethylamiodarone concentration (n=30, r=0.371, p<0.01). The results suggest that there is a significant interaction between amiodarone and metoprolol via desethylamiodarone-induced inhibition of CYP2D6. Therefore, careful monitoring of metoprolol concentrations/bioactivity of CYP2D6 is required in the context of co-administration of amiodarone and metoprolol.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amiodarone,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Arrhythmia Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP2D6,
http://linkedlifedata.com/resource/pubmed/chemical/Metoprolol,
http://linkedlifedata.com/resource/pubmed/chemical/desethylamiodarone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1347-4367
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
501-5
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:17220566-Adult,
pubmed-meshheading:17220566-Aged,
pubmed-meshheading:17220566-Amiodarone,
pubmed-meshheading:17220566-Anti-Arrhythmia Agents,
pubmed-meshheading:17220566-Arrhythmias, Cardiac,
pubmed-meshheading:17220566-Cytochrome P-450 CYP2D6,
pubmed-meshheading:17220566-Drug Interactions,
pubmed-meshheading:17220566-Drug Therapy, Combination,
pubmed-meshheading:17220566-Female,
pubmed-meshheading:17220566-Humans,
pubmed-meshheading:17220566-Male,
pubmed-meshheading:17220566-Metoprolol,
pubmed-meshheading:17220566-Middle Aged
|
pubmed:year |
2006
|
pubmed:articleTitle |
Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia.
|
pubmed:affiliation |
Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study
|